R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga and Tobias S. K ohler

Size: px
Start display at page:

Download "R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga and Tobias S. K ohler"

Transcription

1 Sexual Function/Infertility Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga and Tobias S. K ohler From the Division of Urology, Southern Illinois University School of Medicine (RCW, TSK) and Springfield Clinic (HJW), Springfield and Department of Urology, Northwestern University Feinberg School of Medicine (REB), Chicago, Illinois, Department of Urology, University of Minnesota School of Medicine and Minneapolis Veterans Affairs Healthcare System, Minneapolis (KF), Minnesota, and Glickman Urological and Kidney Institute, Cleveland Clinic Foundation (MM), Cleveland, Ohio Purpose: Based on studies showing the circadian rhythmicity of testosterone the optimal time of day to draw total testosterone in men has classically been reported as between 8 and 11 a.m. However, further studies demonstrated that the testosterone circadian rhythmicity becomes blunted with age. Materials and Methods: We retrospectively reviewed the charts of 2,569 men who presented with erectile dysfunction for total testosterone and draw times. We compared the men by age group, including less than 40 years and 5-year groupings after age 40 years. Total testosterone was analyzed for variability during the most common draw time hours (7 a.m. to 2 p.m.). Results: Mean total testosterone at 7 to 9 a.m. and 9 a.m. to 2 p.m. clinically and statistically differed only in men younger than 40 vs 40 to 44 years old (mean difference 207 ng/dl, 95% CI 98e315, p ¼ vs 149 ng/dl, 95% CI 36e262, p ¼ 0.01). No other group showed a clinically and statistically significant difference between those periods. Conclusions: Total testosterone in men with erectile dysfunction who are younger than 45 years should be drawn as close to 7 a.m. as possible because a statistically and clinically relevant decrease in testosterone will occur during the course of the day. Men older than 45 years with erectile dysfunction can have total testosterone drawn at any time before 2 p.m. without misleading results. Key Words: testis, erectile dysfunction, testosterone, circadian rhythm, age groups THE latest practice guidelines of the Endocrine Society recommend measuring morning TT in men presenting with symptoms of androgen deficiency. 1 The optimal time to draw TT in men has been classically reported as morning 1 to obtain the peak value or specifically between 8 and 11 a.m. 2 Based on 24-hour sequential blood sampling in small subsets of healthy men diurnal variation of TT was clearly demonstrated but this effect is attenuated as men age. 3e7 A large study in men with a mean age of 60 years participating in prostate cancer screening demonstrated that TT remains stable throughout the morning and early afternoon, decreasing only after 2 p.m. 8 No difference was noted in diurnal variation before 2 p.m. In contrast, other researchers reported complete loss of diurnal variation in TT in men with androgen deficiency. 9 Other studies clearly showed the blunting of diurnal variation in TT in older Abbreviations and Acronyms ADT ¼ androgen deprivation therapy ED ¼ erectile dysfunction LH ¼ luteinizing hormone TRT ¼ testosterone replacement therapy TT ¼ total testosterone VA ¼ Veterans Affairs Accepted for publication January 14, Study received Minneapolis VA Hospital institutional review board approval. * Correspondence: Division of Urology, Department of Surgery, Southern Illinois University School of Medicine, 301 North Eighth St., P.O. Box 19649, Springfield, Illinois ( rwelliver@ siumed.edu). Financial interest and/or other relationship with Fertility and Sterility. Financial interest and/or other relationship with Auxilium, Allergan, AMS, Coloplast, AbbVie and Hollister. For another article on a related topic see page /14/ /0 THE JOURNAL OF UROLOGY 2014 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH,INC. Vol. 192, , July 2014 Printed in U.S.A. j 165

2 166 VALIDITY OF MIDDAY TOTAL TESTOSTERONE IN OLDER MEN WITH ERECTILE DYSFUNCTION This is not surprising since TT decreases with age in men. This is thought to occur at a rate of approximately 1% per year beginning around age 40 years. 12 However, the conclusions drawn from screening the general population for low testosterone should be used carefully. Recent Endocrine Society guidelines recommend against screening the general population for androgen deficiency and only recommend screening men with the characteristic symptoms of androgen deficiency. 1 Age dependent effects of diurnal variation remain unclear, particularly in younger men. Additionally, knowing the diurnal variation in TT in men with a classic symptom of androgen deficiency such as ED is likely to be more helpful for determining who and when to screen. Because hypogonadal men typically notice an energy nadir later in the day, perhaps investigating TT levels at that time of maximum bother may provide more insight. Previous literature necessitates asking the question of what time of day testosterone levels can reliably be drawn when considering patient age. 13 We assessed the effect of age on the diurnal variance of TT and reassessed draw time recommendations by determining peak TT values. More clearly establishing acceptable draw times may lead to more patient flexibility in obtaining laboratory values and decrease redundant laboratory testing. men. 5e7,10,11 Separate analysis was done to compare mean TT for the draw times 7 a.m. to 2 p.m. and after 2 p.m. for all patients older than 45 years. Data were analyzed with ExcelÒ and GraphPadÒ statistical calculators using the 2-tailed test with continuity corrections. All results at p <0.05 were considered significant. Checking LH became standard at Minneapolis VA in A subset of men (653 of 2,794 with available TT) also had a LH level drawn as part of the laboratory assessment before the visit. LH and TT in these men were evaluated to determine what percent in the overall study group of 2,569 with TT 50 to 1,000 ng/dl were likely to have hormonal manipulation. Men with undetectable LH but TT between 50 and 1,000 ng/dl were considered to have a confounding additional factor of ADT or TRT. RESULTS Mean age of these patients was 63 years (range 26 to 89). The 65 to 69-year age group had the largest number of patients (532). The extremes of age (26 to 39 years in 46 patients and 80 to 84 years in 43) were least represented. Graphic analysis with smoother curves of scatterplot data of TT by draw times of different age groups showed a large decrease in TT during the day in the youngest 2 groups (less than 40 and 40 to 44 years) (see figure). All other age groups did not MATERIALS AND METHODS This study was approved by the institutional review board at Minneapolis VA Hospital. The computerized charts of all men who presented to the Minneapolis VA ED clinic from 1986 to 2004 with a primary complaint of ED were collected as previously described. 14 These records were then retrospectively reviewed. A total of 3,547 men were evaluated at the ED clinic during this 15-year period. Of these men 2,794 between ages of 26 and 84 years had TT evaluated at least once, including 114 excluded from primary study analysis due to draw time outside a 7 a.m to 2 p.m. range. The 111 men with TT outside the laboratory reference range of greater than 1,000 or less than 50 ng/dl were excluded from study. The remaining 2,569 men were stratified into groups by age, including a 26 to 39-year age group and groups at 5-year age intervals thereafter with 46 or more men per group. The groups were then differentiated into hourly draw times spanning 7 a.m. to 2 p.m. No patient had repeat testosterone measurements included in the data set. These data subgroups were analyzed by scatterplot techniques. Based on the scatterplots and the need for adequate numbers for statistical purposes each age group was separated into 2 groups, including men with a draw time of 7 to 9 a.m. and those with a draw time of 9 a.m. to 2 p.m. The mean TT in each draw time subgroup was compared by each age group using the Student t-test. TT vs draw time in men of different age groups

3 VALIDITY OF MIDDAY TOTAL TESTOSTERONE IN OLDER MEN WITH ERECTILE DYSFUNCTION 167 demonstrate this obvious decrease in TT. In men younger than 45 years the highest TT was predictably seen at the earliest points in the day and the rate of decrease throughout the day was most notable in the morning. Comparing TT measured between 7 and 9 a.m. vs 9 a.m. to 2 p.m. in the different age groups yielded a statistically significant difference in only 3 groups, that is less than 40, 40 to 44 and 70 to 74 years (p ¼ , 0.01 and 0.038, respectively, see table). The difference in mean TT was 207, 149 and 34 ng/dl, respectively. To analyze the TT decrease after 2 p.m. in men older than 45 years TT values in samples drawn after 2 p.m. in 100 patients were also compared to TT values at all draw times before 2 p.m. in 2,462. A statistical difference was seen with mean TT for draw times before 2 p.m. greater than values after 2 p.m. ( vs ng/dl, mean difference 41, 95% CI 7, 75, p ¼ 0.017). Of the 653 men with known LH values only 15 had LH below reference values, implying hormonal manipulation. Six of these 15 men had TT outside the 50 to 1,000 ng/dl range, including 3 with values less than 50 and 3 with values greater than 1,000 ng/dl. By restricting TT to between 50 and 1,000 ng/dl we could then identify 6 of the 15 men (40%) who were Early morning vs late morning/midday TT in men of different age groups Age (No. pts) Time Mean SD TT (ng/dl) Mean ng/dl TT Difference (95% CI) p Value 26e39: 207 (98e315) e9 a.m a.m.e2 p.m e44: 149 (36e262) e9 a.m a.m.e2 p.m e49: 3 ( 64e58) e9 a.m a.m.e2 p.m e54: 20 ( 30e70) e9 a.m a.m.e2 p.m e59: 28 ( 15e71) e9 a.m a.m.e2 p.m e64: 5 ( 32e42) e9 a.m a.m.e2 p.m e69: 7 ( 26e40) e9 a.m a.m.e2 p.m e74: 34 (2e66) e9 a.m a.m.e2 p.m e79: 2 ( 53e57) e9 a.m a.m.e2 p.m e84: 3 ( 75e69) e9 a.m a.m.e2 p.m likely undergoing hormonal manipulation. Only 9 men in the group of 653 had normal range TT and undetectable LH. These patients with potentially unrecognized hormonal manipulation comprised only 1.4% of the study group. DISCUSSION This study further solidifies the circadian rhythmicity of testosterone and the decrease in the effect of this rhythm with increasing age. 3e6,10,15 However, to our knowledge our study differs since we verified this in men with a classic symptom of hypogonadism and quantified the severity of testosterone blunting in relation to patient age. The magnitude of change when comparing the 7 to 9 a.m. interval draw against draws at all other times was clinically and statistically significant in men younger than 40 and 40 to 44 years old (207 and 149 ng/dl, respectively). Although the 70 to 74-year age group showed a statistically significant change (p ¼ 0.038), the clinical significance of a 34 ng/dl difference is questionable. Although statistical analysis was only done to compare the 7 to 9 a.m. and 9 a.m. to 2 p.m. draw times, scatterplots indicated that testosterone decreased rapidly after 7 a.m. in men younger than 45 years. This corresponds to previous sequential blood draw studies showing peak testosterone at approximately 6 to 7 a.m. 7 Values of TT drawn after 2 p.m. were also compared with values at all draw times before 2 p.m. in patients older than 45 years. Our results were similar to those of Crawford et al 8 in that a statistically significant decrease in TT (41 ng/dl, p ¼ 0.017) was noted after 2 p.m. However, definitive conclusions from this point should be tempered due to the limited number of men (100) who had blood drawn after 2 p.m. and the questionable clinical significance of a 41 ng/dl change in TT. Most experts recommend routine TT measurement as a diagnostic tool in men who present with hypogonadal symptoms. Low or low normal TT should be confirmed by repeat TT measurement and in some patients by the free or bioavailable testosterone level. 1 Furthermore, a true diagnosis of hypogonadism requires at least some adverse effect such as ED, low libido, depression, lethargy, osteoporosis, regression of secondary sexual characteristics, or loss of muscle mass or strength. 16 The clinical symptom present in all patients differentiates this study from the prostate cancer screening subgroup in another large study. 8 The cause of a decrease in testosterone production with age is multifactorial and poorly understood. Potential causes include a decrease in the number and alteration of Leydig cells, 17 and age

4 168 VALIDITY OF MIDDAY TOTAL TESTOSTERONE IN OLDER MEN WITH ERECTILE DYSFUNCTION related alterations in the hypothalamic-pituitarygonadal axis. 18 Notable correlations have also been made between decreased sleep quantity with advancing age and decreasing testosterone. 19 A potential confounding factor of this study is the potentially unrecognized use of ADT and TRT in these patients. We mitigated the influence of this possible confounder by analyzing the effect of our exclusion criteria, namely in excluding TT values outside the laboratory reference range. When available, LH values were included in analysis to enable us to draw conclusions on confounding risk in our overall cohort. Generally men who are on ADT or TRT would have undetectable LH due to central repression or feedback, respectively, from these treatments. Checking LH became a standard practice at Minneapolis VA Hospital in 2000 and 94% of men in whom TT was measured between 2000 and 2002 also had LH assessed. This subgroup of 653 men represented 23% of the entire study cohort. After applying our exclusion criteria an acceptably small cohort of only 1.4% of the subgroup would have been on unrecognized hormonal manipulation. Including these men in the data set did not significantly change our results. As we reported previously, 23% of the entire cohort could have been considered hypogonadal using a cutoff point of 300 ng/dl. 20 An ideal study to determine the optimum time to draw TT levels in men stratified by age would be well powered and include multiple repeat bioavailable testosterone samples from the same man on the same day. An ideal study would also record and account for potential confounders of TT such as past medical problems, lifestyle variations, waking time and medication history. Additionally, the study would record any of the well recognized sequelae of hypogonadism (low libido, poor energy, sarcopenia, etc) and stratify patients by these symptoms. Given that patients in our study had TT drawn only once and potential confounders were not recorded, we relied on the law of large numbers to have aggregate mean values of many men (with an averaged confounding risk) for a given period approximate the TT of a future single patient for the same period. Another group drew conclusions based on a similar premise. 8 Although our methodology cannot account for several confounders, our data appropriately corroborate 2 previously proposed principles. 1) The data show a smooth decrease in TT with age. 2) Obvious diurnal variation exists in men younger than 45 years and this effect is blunted in older men. CONCLUSIONS Our study of a single blood draw in a large number of men older than 45 years with ED revealed no difference in mean TT at any time between 7 a.m. and 2 p.m. In men younger than 45 years with ED a draw time after 9 a.m. resulted in significantly lower mean TT. Our data provide unique insight into a large cohort of men with ED, a key symptom of hypogonadism. REFERENCES 1. Bhasin S, Cunningham GR, Hayes FJ et al: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: Wespes E and Schulman CC: Male andropause: myth, reality, and treatment. Int J Impot Res, suppl., 2002; 14: S Marrama P, Carani C, Baraghini GF et al: Circadian rhythm of testosterone and prolactin in the ageing. Maturitas 1982; 4: Plymate SR, Tenover JS and Bremner WJ: Circadian variation in testosterone, sex hormone-binding globulin, and calculated nonsex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 1989; 10: Bremner WJ, Vitiello MV and Prinz PN: Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56: Tenover JS, Matsumoto AM, Clifton DK et al: Age-related alterations in the circadian rhythms of pulsatile luteinizing hormone and testosterone secretion in healthy men. J Gerontol 1988; 43: M Diver MJ, Imtiaz KE, Ahmad AM et al: Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003; 58: Crawford ED, Barqawi AB, O Donnell C et al: The association of time of day and serum testosterone concentration in a large screening population. BJU Int 2007; 100: Gupta SK, Lindemulder EA and Sathyan G: Modeling of circadian testosterone in healthy men and hypogonadal men. J Clin Pharmacol 2000; 40: Montanini V, Simoni M, Chiossi G et al: Age-related changes in plasma dehydroepiandrosterone sulphate, cortisol, testosterone and free testosterone circadian rhythms in adult men. Horm Res 1988; 29: Boyce MJ, Baisley KJ, Clark EV et al: Are published normal ranges of serum testosterone too high? Results of a cross-sectional survey of serum testosterone and luteinizing hormone in healthy men. BJU Int 2004; 94: Harman SM, Metter EJ, Tobin JD et al: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: Morgentaler A: Commentary: guideline for male testosterone therapy: a clinician s perspective. J Clin Endocrinol Metab 2007; 92: Bodie J, Lewis J, Schow D et al: Laboratory evaluations of erectile dysfunction: an evidence based approach. J Urol 2003; 169: 2262.

5 VALIDITY OF MIDDAY TOTAL TESTOSTERONE IN OLDER MEN WITH ERECTILE DYSFUNCTION El-Sakka AI and Hassoba HM: Age related testosterone depletion in patients with erectile dysfunction. J Urol 2006; 176: Nieschlag E, Swerdloff R, Behre HM et al: Investigation, treatment and monitoring of lateonset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Eur Urol 2005; 48: Neaves WB, Johnson L, Porter JC et al: Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab 1984; 59: Deslypere JP and Vermeulen A: Aging and tissue androgens. J Clin Endocrinol Metab 1981; 53: Penev PD: Association between sleep and morning testosterone levels in older men. Sleep 2007; 30: K ohler TS, Kim J, Feia K et al: Prevalence of androgen deficiency in men with erectile dysfunction. Urology 2008; 71: 693.

The association of time of day and serum testosterone concentration in a large screening population

The association of time of day and serum testosterone concentration in a large screening population Original Article TIME OF DAY AD SERUM TESTOSTEROE LEVEL I A LARGE SCREEIG POPULATIO CRAWFORD et al. Authors from the USA reviewed semen samples for their ational Prostate Cancer Awareness screening programme.

More information

6/14/2010. GnRH=Gonadotropin-Releasing Hormone.

6/14/2010. GnRH=Gonadotropin-Releasing Hormone. Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression

More information

Testosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E

Testosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a

More information

PRISM Bruges June Herman Leliefeld Urologist. The Netherlands

PRISM Bruges June Herman Leliefeld Urologist. The Netherlands PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up

More information

Men Getting Older Will Testosterone Keep Him Young?

Men Getting Older Will Testosterone Keep Him Young? Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and

More information

Sexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon. DOI: /kju

Sexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon.  DOI: /kju www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone

More information

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency

More information

ISSN: (print), (electronic)

ISSN: (print), (electronic) http://informahealthcare.com/tam ISSN: 1368-5538 (print), 1473-0790 (electronic) Aging Male, 2014; 17(3): 147 154! 2014 Informa UK Ltd. DOI: 10.3109/13685538.2014.908460 ORIGINAL ARTICLE Performance of

More information

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical

More information

BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE

BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation

More information

testosterone and LH concentrations in the morning ( hours) and evening ( hours).

testosterone and LH concentrations in the morning ( hours) and evening ( hours). Original Article SERUM TESTOSTERONE AND LH IN HEALTHY MEN BOYCE et al. Are published normal ranges of serum testosterone too high? Results of a cross-sectional survey of serum testosterone and luteinizing

More information

Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy

Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy ORIGINAL ARTICLE Vol. 41 (6): 1167-1171, November. December, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0528 Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy

More information

How to treat: TRT modalities and formulations

How to treat: TRT modalities and formulations How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement

More information

In addition to critical development and reproductive

In addition to critical development and reproductive Journal of Andrology, Vol. 33, No. 6, November/December 2012 Copyright E American Society of Andrology Seasonal Fluctuations in Testosterone-Estrogen Ratio in Men From the Southwest United States DANIEL

More information

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated. Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology

More information

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.

More information

Keywords: Position statement, expert opinion, hypogonadism, men, testosterone, calculated bioavailable testosterone

Keywords: Position statement, expert opinion, hypogonadism, men, testosterone, calculated bioavailable testosterone The Aging Male, December 2007; 10(4): 211 216 WORKSHOP REPORT Functional testosterone: Biochemical assessment of hypogonadism in men Report from a multidisciplinary workshop hosted by the Ontario Society

More information

Point-Counterpoint: Late Onset Hypogonadism (LOH)

Point-Counterpoint: Late Onset Hypogonadism (LOH) Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx

More information

ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN

ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency

More information

Update on diagnosis and complications of adult and elderly male hypogonadism

Update on diagnosis and complications of adult and elderly male hypogonadism Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism

More information

HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)

HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION

More information

Hypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018

Hypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018 Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017

More information

THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION

THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION Aksam A. Yassin MD PhD EdD FEBU Professor of Urology & Human Sexuality Institute of Urology & Andrology, Segeberger

More information

What Is the Low T Syndrome? Is Testosterone Supplementation Safe?

What Is the Low T Syndrome? Is Testosterone Supplementation Safe? What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or

More information

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Pellet (Testopel) Reference Number: CP.PHAR.354 Effective Date: 08.01.17 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the

More information

Androgens. Medication Strengths Quantity Limit Comments Androderm (testosterone patch) 1% pump 2 pump bottles per Non-Preferred

Androgens. Medication Strengths Quantity Limit Comments Androderm (testosterone patch) 1% pump 2 pump bottles per Non-Preferred Market DC Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Androderm (testosterone patch) AndroGel (testosterone

More information

Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University

Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a

More information

Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study

Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.619 Sexual Dysfunction/Male Infertility Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study Sungmin

More information

Testosterone Injection and Implant

Testosterone Injection and Implant Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone

More information

Testosterone Injection / Implant

Testosterone Injection / Implant Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone

More information

Does TRT Induce Prostate Cancer?

Does TRT Induce Prostate Cancer? Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there

More information

An Update on Men s Health and Sexual Function

An Update on Men s Health and Sexual Function An Update on Men s Health and Sexual Function Lawrence Jenkins, MD, MBA Assistant Professor Clinical Department of Urology The Ohio State University Wexner Medical Center Outline Testosterone Deficiency

More information

Testosterone Injection and Implant

Testosterone Injection and Implant Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone

More information

The main outcome measures were predictors of response and long-term results with long-term CC therapy in hypogonadal patients.

The main outcome measures were predictors of response and long-term results with long-term CC therapy in hypogonadal patients. BJUI BJU INTERNATIONAL Clomiphene citrate is safe and effective for long-term management of hypogonadism Daniel J. Moskovic, Darren J. Katz, Ardavan Akhavan, Kelly Park and John P. Mulhall Sexual & Reproductive

More information

ORIGINAL ARTICLE The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism

ORIGINAL ARTICLE The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism (21) 22, 2 24 & 21 Nature Publishing Group All rights reserved 955-993/1 $32. www.nature.com/ijir ORIGINAL ARTICLE : a new tool in quantifying the severity of hypogonadism O Mohamed 1, RE Freundlich 1,

More information

HORMONE THERAPY IN AGING MALE ATHLETES

HORMONE THERAPY IN AGING MALE ATHLETES DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the

More information

The clinical importance of testosterone in men with type 2 diabetes

The clinical importance of testosterone in men with type 2 diabetes 22 The clinical importance of testosterone in men with type 2 diabetes GEOFF HACKETT Although the association of low testosterone with type 2 diabetes is well established, testosterone levels are not routinely

More information

Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl

Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl Sexual Medicine Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl Jason M. Scovell, Ranjith Ramasamy, Nathan Wilken, Jason R. Kovac and Larry I. Lipshultz

More information

administered before treatment and during follow-up.

administered before treatment and during follow-up. BJUI Outcomes of clomiphene citrate treatment in young hypogonadal men Darren J. Katz, Omar Nabulsi, Raanan Tal and John P. Mulhall Male Sexual and Reproductive Medicine Programme, Urology Service, Department

More information

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description

More information

Older Age Is Associated With Similar Improvements in Semen Parameters and Testosterone After Subinguinal Microsurgical Varicocelectomy

Older Age Is Associated With Similar Improvements in Semen Parameters and Testosterone After Subinguinal Microsurgical Varicocelectomy Older Age Is Associated With Similar Improvements in Semen Parameters and Testosterone After Subinguinal Microsurgical Varicocelectomy Wayland Hsiao, James S. Rosoff, Joseph R. Pale, Eleni A. Greenwood

More information

EAU GUIDELINES ON MALE HYPOGONADISM

EAU GUIDELINES ON MALE HYPOGONADISM EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by

More information

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY

More information

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine

More information

EAU GUIDELINES ON MALE HYPOGONADISM

EAU GUIDELINES ON MALE HYPOGONADISM EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen

More information

HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01.

HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01. Testosterone Therapy and Mortality Risk Michael L. Eisenberg, MD 1, Shufeng Li, MS 2, Danielle Herder, MD 3, Dolores J. Lamb, PhD 4, and Larry I. Lipshultz, MD 4 1 Assistant Professor, Departments of Urology

More information

BJUI. Second to fourth digit ratio, adult testosterone level and testosterone deficiency

BJUI. Second to fourth digit ratio, adult testosterone level and testosterone deficiency . 2011 Sexual Medicine SECOND TO FOURTH DIGIT RATIO, ADULT TESTOSTERONE LEVEL AND TESTOSTERONE DEFICIENCY GARCÍA-CRUZ ET AL. BJUI Second to fourth digit ratio, adult testosterone level and testosterone

More information

Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products.

Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology

More information

Implantable Hormone Pellets

Implantable Hormone Pellets Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Testosterone Injection and Implant

Testosterone Injection and Implant Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone

More information

Over the past decade, androgen replacement

Over the past decade, androgen replacement J. Andrew Hoover, MD; Jeffrey T. Kirchner, DO, FAAFP Department of Family and Community Medicine, Lancaster General Hospital, Pa jhoover4@lghealth.org The authors reported no potential conflict of interest

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Testosterone Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 7 References... 7 Effective Date... 1/1/2018

More information

Prevalence of hypogonadism in males aged at least 45 years: the HIM study

Prevalence of hypogonadism in males aged at least 45 years: the HIM study ORIGINAL PAPER doi: 10.1111/j.1742-1241.2006.00992.x Prevalence of hypogonadism in males aged at least 45 years: the HIM study T. MULLIGAN, 1 M. F. FRICK, 2 Q. C. ZURAW, 2 A. STEMHAGEN, 2 C. MCWHIRTER

More information

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal

More information

Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)

Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John

More information

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: June 24, 2016 Testosterone Oral Buccal Nasal Description

More information

Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline

Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline SPECIAL FEATURE Clinical Practice Guideline Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Shalender Bhasin, Glenn R. Cunningham, Frances

More information

GUIDELINES ON MALE HYPOGONADISM

GUIDELINES ON MALE HYPOGONADISM GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen

More information

Testosterone and the Prostate

Testosterone and the Prostate Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive

More information

TRT and localized protate cancer

TRT and localized protate cancer TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be

More information

Testosterone levels in men with erectile dysfunction

Testosterone levels in men with erectile dysfunction Original Article TESTOSTERONE LEVELS IN MEN WITH ED MARTÍNEZ-JABALOYAS et al. Testosterone levels in men with erectile dysfunction JOSÉ M. MARTÍNEZ-JABALOYAS, ALFONSO QUEIPO-ZARAGOZÁ*, FRANCISCO PASTOR-HERNÁNDEZ,

More information

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research

More information

Didactic Series. Hypogonadism and HIV. Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016

Didactic Series. Hypogonadism and HIV. Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016 Didactic Series Hypogonadism and HIV Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016 This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department

More information

Clomiphene citrate treatment for late onset hypogonadism: rise and fall

Clomiphene citrate treatment for late onset hypogonadism: rise and fall ORIGINAL ARTICLE Vol. 42 (x): 2016 July 4.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2016.0112 Clomiphene citrate treatment for late onset hypogonadism: rise and fall Marcelo Marconi 1, Renato Souper

More information

ANDROGEN DEFICIENCY/MALE HYPOGONADISM

ANDROGEN DEFICIENCY/MALE HYPOGONADISM ANDROGEN DEFICIENCY/MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (androgen deficiency)

More information

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of

More information

Testosterone therapy and cancer risk

Testosterone therapy and cancer risk Sexual Medicine Testosterone therapy and cancer risk Michael L. Eisenberg*, Shufeng Li*, Paul Betts, Danielle Herder, Dolores J. Lamb and Larry I. Lipshultz Departments of *Urology, Obstetrics/Gynecology

More information

Preparing for the road ahead. LEARN MORE ABOUT these 5 risks

Preparing for the road ahead. LEARN MORE ABOUT these 5 risks Preparing for the road ahead LEARN MORE ABOUT these 5 risks to A MAN S health 3 4 5 2 6 1 7 0 8 9 WHY DOES IT SEEM LIKE SOME MEN TAKE BETTER CARE OF THEIR CARS THAN THEIR OWN HEALTH? When the check engine

More information

The effects of opioids on the endocrine system: Ali, Koddus; Raphael, Jon; Khan, Salim; Labib, Mourad H.; Duarte, Rui

The effects of opioids on the endocrine system: Ali, Koddus; Raphael, Jon; Khan, Salim; Labib, Mourad H.; Duarte, Rui The effects of opioids on the endocrine system: Ali, Koddus; Raphael, Jon; Khan, Salim; Labib, Mourad H.; Duarte, Rui DOI: 10.1136/postgradmedj-2016-134299 License: Creative Commons: Attribution-NonCommercial-NoDerivs

More information

One Day Hormone Check

One Day Hormone Check One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND

More information

Testosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014

Testosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Testosterone Replacement Therapy & Monitoring in HIV Infected Men Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Acknowledgement Ramona Bhatia MD (HIV Research Fellow, First Author) Chad Achenbach MD (HIV

More information

Evaluation and Management of Pituitary Failure. Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS

Evaluation and Management of Pituitary Failure. Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS Evaluation and Management of Pituitary Failure Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS Conflict of Interest None Objectives Diagnostic approach

More information

ANDROGEN DEFICIENCY Update on Evaluation and Management

ANDROGEN DEFICIENCY Update on Evaluation and Management ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of

More information

Androgen deficiency in men has attracted much

Androgen deficiency in men has attracted much Journal of Andrology, Vol. 33, No. 5, September/October 2012 Copyright E American Society of Andrology The Comparison of the Aging Male Symptoms (AMS) Scale and Androgen Deficiency in the Aging Male (ADAM)

More information

EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE

EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics

More information

Diagnosis, Treatment, and Follow-up of Men with Androgen Deficiency

Diagnosis, Treatment, and Follow-up of Men with Androgen Deficiency Physician Performance Measurement Set Approved May 2012 Endocrine Society 2055 L Street, NW, Suite 600 Washington, DC 20036 (P) 202-971-3636 (F) 202-736-9706 endocrine.org Background These clinical performance

More information

TESTOSTERONE DEFINITION

TESTOSTERONE DEFINITION DEFINITION A hormone that is a hydroxyl steroid ketone (C19H28O2) produced especially by the testes or made synthetically and that is responsible for inducing and maintaining male secondary sex characteristics.

More information

Update on male reproductive endocrinology

Update on male reproductive endocrinology Review Article Update on male reproductive endocrinology Raul I. Clavijo 1, Wayland Hsiao 2 1 Department of Urology, University of California, Davis, School of Medicine, Sacramento, California, USA; 2

More information

Exogenous testosterone: a preventable cause of male infertility

Exogenous testosterone: a preventable cause of male infertility Review Article Exogenous testosterone: a preventable cause of male infertility Lindsey E. Crosnoe 1, Ethan Grober 2, Dana Ohl 3, Edward D. Kim 1 1 University of Tennessee Graduate School of Medicine, Knoxville,

More information

Is T for Me? Testosterone Replacement Therapy in Older Males

Is T for Me? Testosterone Replacement Therapy in Older Males Is T for Me? Testosterone Replacement Therapy in Older Males Natalia Malesa, PharmD, MSIS PGY1 Community Pharmacy Resident H-E-B Pharmacy The University of Texas at Austin Objectives At the end of this

More information

Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany

Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.

More information

Therapeutic Cohort Results

Therapeutic Cohort Results Patient: JANE DOE DOB: December 31, 1968 Sex: F MRN: Order Number: Completed: February 26, 2016 Received: February 26, 2016 Collected: February 26, 2016 One Day Hormone Check - Salivary Profile Therapeutic

More information

Sexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist

Sexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with

More information

Androgen Pattern and Erectile Function in Newly Diagnosed Type 2 Diabetes

Androgen Pattern and Erectile Function in Newly Diagnosed Type 2 Diabetes Med. J. Cairo Univ., Vol. 84, No. 3, December: 341-347, 2016 www.medicaljournalofcairouniversity.net Androgen Pattern and Erectile Function in Newly Diagnosed Type 2 Diabetes AHMED I. EL-SAKKA, M.D.*;

More information

Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes:

Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: The Endocrine Society s CLINICAL GUIDELINES Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Authors: Shalender Bhasin, Glenn R. Cunningham,

More information

Gonadal Hormones and Gonadotrophins in healthy males beyond forty years Abdul Jalil Ansari 1, SAM Golam Kibria 2, Fakhrul Islam 3

Gonadal Hormones and Gonadotrophins in healthy males beyond forty years Abdul Jalil Ansari 1, SAM Golam Kibria 2, Fakhrul Islam 3 Original Article Gonadal Hormones and Gonadotrophins in healthy males beyond forty years Abdul Jalil Ansari 1, SAM Golam Kibria 2, Fakhrul Islam 3 Rajshahi Medical College, Rajshahi 1, Bangabandhu Sheikh

More information

Can men on AS be treated with testosterone?

Can men on AS be treated with testosterone? Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering

More information

Testim 1 Gel: Review of Clinical Data

Testim 1 Gel: Review of Clinical Data European Urology Supplements European Urology Supplements 4 (2005) 24 30 Testim 1 Gel: Review of Clinical Data Tom A. McNicholas* Department of Urology, Lister Hospital, Corey s Mill Lane, Stevenage, Hertfordshire

More information

GUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde

GUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely

More information

ANDROGEN DEFICIENCY/MALE HYPOGONADISM

ANDROGEN DEFICIENCY/MALE HYPOGONADISM Medical Information to Support the Decisions of TUE Committees 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of

More information

Late Onset Hypogonadism. Toh Charng Chee Hospital Selayang

Late Onset Hypogonadism. Toh Charng Chee Hospital Selayang Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of

More information

The Effectiveness of Clomiphene Citrate Compared to Exogenous Testosterone Therapy in Adult Males

The Effectiveness of Clomiphene Citrate Compared to Exogenous Testosterone Therapy in Adult Males Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-8-2015 The Effectiveness of Clomiphene Citrate Compared to Exogenous Testosterone

More information

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008

More information

Andropause state of the art 2015 and review of selected aspects

Andropause state of the art 2015 and review of selected aspects DOI: 10.5114/pm.2015.49998 Prz Menopauzalny 2015; 14(1): 1-6 Featured paper Andropause state of the art 2015 and review of selected aspects Grzegorz Jakiel 1, Marta Makara-Studzińska 2, Michał Ciebiera

More information

Therapeutic Cohort Results

Therapeutic Cohort Results Patient: SAMPLE PATIENT DOB: Sex: MRN: Menopause Plus - Salivary Profile Therapeutic Cohort Results Hormone Average Result QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th Therapeutic Range* Estradiol (E2) 8.7

More information

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline CLINICAL PRACTICE GUIDELINE Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline Shalender Bhasin, 1 Juan P. Brito, 2 Glenn R. Cunningham, 3 Frances J. Hayes,

More information

Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D.

Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D. The General Practice Education Day Healthed / Generation Next August 22 nd Sydney Update on Androgen Deficiency Robert I. McLachlan, FRACP, PhD Director, Andrology Australia Principal Research Fellow,

More information

Predicting Biochemical Response to Clomiphene Citrate in Men with Hypogonadism

Predicting Biochemical Response to Clomiphene Citrate in Men with Hypogonadism 2302 Predicting Biochemical Response to Clomiphene Citrate in Men with Hypogonadism Clarisse R. Mazzola, MD,* Darren J. Katz, MD,* Nina Loghmanieh, DO,* Christian J. Nelson, PhD,* and John P. Mulhall,

More information